Xianwei Bu

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper et al. · Annals of the Rheumatic Diseases · 2022 · 124 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Roy Fleischmann, Eduardo Mysler, Louis Bessette et al. · RMD Open · 2022 · 103 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study

Philip J. Mease, Apinya Lertratanakul, Kim Papp et al. · Rheumatology and Therapy · 2021 · 79 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study

Roy Fleischmann, Jerzy Świerkot, Patrick Durez et al. · RMD Open · 2024 · 26 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17

Comparison between adalimumab introduction and methotrexate dose escalation in patients with inadequately controlled psoriatic arthritis (CONTROL): a randomised, open-label, two-part, phase 4 study

Laura C. Coates, William Tillett, Maria Antonietta D’Agostino et al. · The Lancet Rheumatology · 2022 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12